Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.

MLA

Kobayashi, Takayuki, et al. “Absolute Lymphocyte Count Predicts Efficacy of Palbociclib in Patients with Metastatic Luminal Breast Cancer.” BMC Cancer, vol. 24, no. 1, Sept. 2024, p. 1156. EBSCOhost, https://doi.org/10.1186/s12885-024-12941-z.

APA

Kobayashi, T., Nishimura, M., Hosonaga, M., Kizawa, R., Kawai, S., Aoyama, Y., Ozaki, Y., Fukada, I., Hara, F., Takano, T., & Ueno, T. (2024). Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer. BMC Cancer, 24(1), 1156. https://doi.org/10.1186/s12885-024-12941-z

Chicago

Kobayashi, Takayuki, Meiko Nishimura, Mari Hosonaga, Rika Kizawa, Saori Kawai, Yosuke Aoyama, Yukinori Ozaki, et al. 2024. “Absolute Lymphocyte Count Predicts Efficacy of Palbociclib in Patients with Metastatic Luminal Breast Cancer.” BMC Cancer 24 (1): 1156. doi:10.1186/s12885-024-12941-z.